FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140187740> ?p ?o ?g. }

• W2140187740 endingPage "314" @default.
• W2140187740 startingPage "305" @default.
• W2140187740 abstract "Abstract The approach to the treatment of acute promyelocytic leukemia (APL) has changed dramatically over the past decade and, as a result, the long-term event-free survival for patients has improved significantly. The addition of the vitamin A derivative, all-trans-retinoic acid (ATRA), to treatment regimens has been responsible for this improvement in survival. Although ATRA is a potent remission induction agent in APL, continuous administration of ATRA as a single agent does not maintain patients in remission. Although lower plasma concentrations were initially noted at the time of relapse in patients with APL, subsequent studies have demonstrated that the decline in plasma drug concentrations occurs within one to two weeks of initiation of treatment, and possibly as early as three days. The inability to maintain adequate plasma concentrations of ATRA because of rapid upregulation of its catabolism is an attractive hypothesis to explain the inevitable recurrences in patients with initially responsive disease, but more recent data suggest that this mechanism alone is unlikely to be responsible for drug resistance. Cellular retinoic acid binding proteins (CRABPs) play a critical role in regulating the amount of free retinoic acid capable of reaching and activating nuclear receptors. Recent studies using leukemic blasts obtained at the time of relapse have demonstrated a shift in the ATRA dose-response curve in vitro. In addition, there is an upregulation in the expression of CRABP in leukemic blasts obtained at relapse. These observations suggest that ATRA resistance is not simply an inability to maintain therapeutic plasma concentrations of drug, but rather may be linked to the intracellular regulation of drug. The intricate nature of the homeostatic mechanisms that maintain tight control over retinoids, combined with the multiplicity of retinoid receptors and signaling pathways, leave open the possibility of a yet-to-be-defined mechanism of resistance that is independent of the clinical pharmacology of ATRA." @default.
• W2140187740 created "2016-06-24" @default.
• W2140187740 creator A5066484657 @default.
• W2140187740 date "1996-10-01" @default.
• W2140187740 modified "2023-10-03" @default.
• W2140187740 title "All-<i>Trans</i>-Retinoic Acid Pharmacology and Its Impact on the Treatment of Acute Promyelocytic Leukemia" @default.
• W2140187740 cites W1481447507 @default.
• W2140187740 cites W1511319187 @default.
• W2140187740 cites W1542216061 @default.
• W2140187740 cites W1554600230 @default.
• W2140187740 cites W1570165358 @default.
• W2140187740 cites W1585061487 @default.
• W2140187740 cites W1607326348 @default.
• W2140187740 cites W189999947 @default.
• W2140187740 cites W1965388358 @default.
• W2140187740 cites W1970096907 @default.
• W2140187740 cites W1974839297 @default.
• W2140187740 cites W1981044274 @default.
• W2140187740 cites W1984509210 @default.
• W2140187740 cites W1985714890 @default.
• W2140187740 cites W1987269203 @default.
• W2140187740 cites W1987445229 @default.
• W2140187740 cites W1987760741 @default.
• W2140187740 cites W1995369623 @default.
• W2140187740 cites W2001515095 @default.
• W2140187740 cites W2007831455 @default.
• W2140187740 cites W2008335233 @default.
• W2140187740 cites W2014591899 @default.
• W2140187740 cites W2017578370 @default.
• W2140187740 cites W2019529484 @default.
• W2140187740 cites W2019644196 @default.
• W2140187740 cites W2034987983 @default.
• W2140187740 cites W2041270901 @default.
• W2140187740 cites W2048572117 @default.
• W2140187740 cites W2049791242 @default.
• W2140187740 cites W2049828237 @default.
• W2140187740 cites W2055879119 @default.
• W2140187740 cites W2060865001 @default.
• W2140187740 cites W2068608642 @default.
• W2140187740 cites W2072233737 @default.
• W2140187740 cites W2076108719 @default.
• W2140187740 cites W2076319483 @default.
• W2140187740 cites W2083436346 @default.
• W2140187740 cites W2085312769 @default.
• W2140187740 cites W2091787441 @default.
• W2140187740 cites W2102191600 @default.
• W2140187740 cites W2103066583 @default.
• W2140187740 cites W2115494923 @default.
• W2140187740 cites W2115874632 @default.
• W2140187740 cites W2122279158 @default.
• W2140187740 cites W2134001087 @default.
• W2140187740 cites W2141083396 @default.
• W2140187740 cites W2145087519 @default.
• W2140187740 cites W2177441413 @default.
• W2140187740 cites W2185703542 @default.
• W2140187740 cites W2186664997 @default.
• W2140187740 cites W2256214571 @default.
• W2140187740 cites W2311386778 @default.
• W2140187740 cites W2318214416 @default.
• W2140187740 cites W2327237185 @default.
• W2140187740 cites W2343463909 @default.
• W2140187740 cites W2407345634 @default.
• W2140187740 cites W2412922958 @default.
• W2140187740 cites W2443384920 @default.
• W2140187740 cites W298378544 @default.
• W2140187740 cites W37960569 @default.
• W2140187740 cites W4230033805 @default.
• W2140187740 cites W4244737196 @default.
• W2140187740 cites W4246713397 @default.
• W2140187740 cites W79968274 @default.
• W2140187740 cites W2024479861 @default.
• W2140187740 doi "https://doi.org/10.1634/theoncologist.1-5-305" @default.
• W2140187740 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10388008" @default.
• W2140187740 hasPublicationYear "1996" @default.
• W2140187740 type Work @default.
• W2140187740 sameAs 2140187740 @default.
• W2140187740 citedByCount "45" @default.
• W2140187740 countsByYear W21401877402012 @default.
• W2140187740 countsByYear W21401877402013 @default.
• W2140187740 countsByYear W21401877402014 @default.
• W2140187740 countsByYear W21401877402015 @default.
• W2140187740 countsByYear W21401877402016 @default.
• W2140187740 countsByYear W21401877402017 @default.
• W2140187740 countsByYear W21401877402018 @default.
• W2140187740 countsByYear W21401877402019 @default.
• W2140187740 countsByYear W21401877402020 @default.
• W2140187740 countsByYear W21401877402021 @default.
• W2140187740 countsByYear W21401877402022 @default.
• W2140187740 crossrefType "journal-article" @default.
• W2140187740 hasAuthorship W2140187740A5066484657 @default.
• W2140187740 hasBestOaLocation W21401877401 @default.
• W2140187740 hasConcept C104317684 @default.
• W2140187740 hasConcept C114851261 @default.
• W2140187740 hasConcept C126322002 @default.
• W2140187740 hasConcept C127561419 @default.
• W2140187740 hasConcept C203014093 @default.
• W2140187740 hasConcept C2776601000 @default.
• W2140187740 hasConcept C2778461978 @default.

• next